Brief: Active Biotech Reports Positive Top-Line Results From LION Study
05/05/2025 12:03
May 5 (Reuters) - Active Biotech AB publ ACTI.ST: ACTIVE BIOTECH REPORTS POSITIVE TOP-LINE RESULTS FROM THE LION STUDY ON OCULAR ABSORPTION AND DISTRIBUTION OF LAQUINIMOD IN THE EYE LAQUINIMOD EYE DROP TREATMENT WAS SAFE AND TOLERABLE DURING 14 DAYS' ADMINISTRATION ACNO DOSE-LIMITING TOXICITIES WERE REPORTED IN ANY OF SUBJECTS Source text: ID:nMFN2WfCRP Further company coverage: ACTI.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million